Rosuvastatin is a member of the drug class of statins, lowering high cholesterol and triglycerides in certain patients. It is recommended to be used only after other measures such as diet and exercise.
It is used to slow atherosclerosis (narrowing of the arteries) in patients with high blood cholesterol levels.
It is also used in certain patients to reduce the risk of heart attack or stroke.
Mechanism of action:
It acts by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.
If one allergic to any ingredient in Rosuvastatin.
In pregnancy and breast feeding.
In active liver disease or abnormal liver function.
If one addicted to alcohol or a history of alcohol abuse.
More serious side effect are muscle pain, tenderness, lack of energy, fever, chest pain, jaundice, dark colored, or foamy urine, pain in the upper right part of the abdomen, loss of appetite, flu-like symptoms, sore throat, chills.
Rosuvastatin may have negative interaction with following drugs:
Prasugrel is used either alone or along with aspirin by patients with recent heart attack, unstable angina, who undergo a certain angioplasty.
Mechanism of action:
Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. These agents reduce the aggregation of platelets by irreversibly binding to P2Y12 receptors.
Prasugrel should not be given to patients with active pathological bleeding, such as peptic ulcer or a history of transient ischemic attack or stroke, because of higher risk of stroke.
Abnormal Liver, abdominal bleeding, decreased blood platelets, decreased white blood cells, decreased blood platelets, decreased white blood, Giant Hives.
Prasugrel on coadministration with NSAIDS and warfarin may increase the risk of bleeding.
Aspirin, also known as acetylsalicylic acid [ASA], often used as an analgesic to relieve minor pains and to reduce fever (antipyretic), and as an anti-inflammatory medication. It is also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels and block blood vessels.
It is used long-term, at low doses, to help prevent heart attacks, strokes, and blood clot formation in people at high risk of developing blood clots.
Mechanism of action: The effect of asprin is dose dependent as below:
Low doses (75 to 150 mg/day) are sufficient to irreversibly acetylate serine 530 of cyclooxygenase (COX)-1 leads to inhibition of platelet generation of thromboxane A2, resulting in an antithrombotic effect.
Intermediate doses (650 mg to 4 g/day) inhibit COX-1 and COX-2, blocking prostaglandin (PG) production, and have analgesic and antipyretic effects.
Gastrointestinal ulcers, stomach bleeding, and ringing in the ears, especially with higher doses.
In children and adolescents, aspirin is not recommended for flu-like symptoms or viral illnesses, because of the risk of Reye's syndrome.
Asprin may interact with alcohol, corticosteroids, analgin.
Asprin on concurrent administration with Phenylbutazone and oxyphenbutazonen may increase risk of GI ulceration.
It may potentiate the effects of of anticoagulants, methotrexate and oral hypoglycemic drugs.
CompositionRabeprazole (20 mg) SALT INFORMATIONRabeprazole (20 mg) TYPICAL USAGE Benign gastric and peptic ulcer. Erosive of ulcerative gastro-oesophageal reflux disease (GORD). Acid peptic disease. SIDE EFFECTS Nausea, stomach upset, skin rash, acute toxicity. DRUG INTERACTION There have been reports of an increase in the effect of the blood thinner, warfarin (Coumadin), by rabeprazole which theoretically could lead to increased bleeding. Patients taking warfarin should be monitored more frequently if they begin taking rabeprazole. Rabeprazole may reduce the elimination of cyclosporin in the liver, thereby increasing cyclosporin levels in the blood and potentially leading to cyclosporin toxicity. The absorption of certain drugs may be affected by changes in stomach acidity. Rabeprazole and other PPIs that reduce stomach acid reduce the absorption and concentration in blood ofketoconazole (Nizoral) and increase the absorption and concentration in blood of digoxin (Lanoxin). This may lead to reduced effectiveness of ketoconazole or increased digoxin toxicity, respectively. PPIs may decrease blood levels of atazanavir (Reyataz). MECHANISM OF ACTION Rabeprazole is an oral drug that is used for the treatment of conditions caused by acid. It is in a class of drugs called proton pump inhibitors or PPIs which block the production of acid by the stomach. Other drugs in the same class include lansoprazole (Prevacid),omeprazole (Prilosec), pantoprazole (Protonix), esomeprazole (Nexium), and dexlansoprazole (Dexilant). PPIs are used for the treatment of acid-caused conditions such as stomach and duodenal ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison Syndrome. Rabeprazole, like other PPIs, blocks the pump in the wall of the stomach that secretes acid into the stomach. By blocking the pump, the secretion of acid into the stomach is decreased, and this allows ulcers in the stomach and esophagus to heal. The FDA approved rabeprazole in August 1999.